{Reference Type}: Journal Article
{Title}: MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.
{Author}: Yuan P;Xue X;Qiu T;Ying J;
{Journal}: Ther Adv Med Oncol
{Volume}: 16
{Issue}: 0
{Year}: 2024
{Factor}: 5.485
{DOI}: 10.1177/17588359231221910
{Abstract}: MET alterations, including MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion, play pivotal roles in primary tumorigenesis and acquired resistance to targeted therapies, especially EGFR tyrosine kinase inhibitors. They represent important diagnostic, prognostic, and predictive biomarkers in many solid tumor types. However, the detection of MET alterations is challenging due to the complexity of MET alterations and the diversity of platform technologies. Therefore, techniques with high sensitivity, specificity, and reliable molecular detection accuracy are needed to overcome such hindrances and aid in biomarker-guided therapies. The current review emphasizes the role of MET alterations as oncogenic drivers in a variety of cancers and their involvement in the development of resistance to targeted therapies. Moreover, our review provides an overview of and recommendations on the selection of various cross-platform technologies for the detection of MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion. Furthermore, challenges and hurdles underlying these common detection platforms are discussed.